Local News

• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer May 08, 2008  
• Zevalin revenues lead Cell Therapeutics's first quarter 2008 financial results  Cell Therapeutics reported financial results for the quarter ended March 31, 2008. Total revenues for the quarter were $3.4 million compared to $20,000 for the first quarter of 2007. Gross product sales of Zevalin(R) (Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.
  Cell Therapeutics, Inc. May 08, 2008  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca May 08, 2008  
• Dendreon reports first quarter 2008 financial results  Dendreon reported results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $31,000 compared to $80,000 for the quarter ended March 31, 2007.
  Dendreon Corporation May 08, 2008  
• Invitrogen and WARF sign license agreement for human embryonic stem cells  Invitrogen and the Wisconsin Alumni Research Foundation, the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for human embryonic stem cell patents for the development of research tools.
  Invitrogen Corporation May 08, 2008  
• FDA approves Strattera(R) for maintenance of ADHD in children and adolescents  Eli Lilly and Company announced that the United States Food and Drug Administration has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents.
  Eli Lilly and Company May 08, 2008  
• Boston Scientific announces dismissal of Johnson & Johnson patent lawsuit in Canada  Boston Scientific announced that the Canadian Federal Court has issued judgment in a lawsuit in which Johnson & Johnson had accused the Company's NIR(R) stent of infringing two Johnson & Johnson Palmaz patents.
  Boston Scientific Corporation May 08, 2008  
• Nastech announces first quarter 2008 financial results  Nastech Pharmaceutical reported financial results for the quarter ended March 31, 2008. Revenue for the three months ended March 31, 2008, was $1.3 million, compared to $5.0 million for the three months ended March 31, 2007.
  Nastech Pharmaceutical Company Inc. May 08, 2008  
• Acucela files Investigational New Drug Application  Acucela announces that it has filed an investigational new drug application to conduct a Phase 1 clinical trial for its compound ACU-02 with the FDA. ACU-02 is an orally available small molecule modulator of the visual cycle thought to play a key role in the pathophysiology of the dry form of AMD.
  Acucela Inc. May 07, 2008  
• Oncothyreon reports first quarter 2008 financial results  Oncothyreon reported a net loss of $5.1 million or $0.26 per basic and diluted share for the quarter ended March 31, 2008, compared with $4.7 million or $0.24 per basic and diluted share for the comparable period in 2007.
  Oncothyreon Inc. May 07, 2008  

   (next 10 articles)